Holen Sie sich die Stockscreener-App
48.89
3.41%
1.61
Vorhandelsmarkt:
48.33
-0.56
-1.15%
Schlusskurs vom Vortag:
$47.28
Offen:
$48.03
24-Stunden-Volumen:
777.10K
Relative Volume:
0.68
Marktkapitalisierung:
$3.88B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-8.2306
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
+7.40%
1M Leistung:
-1.27%
6M Leistung:
+11.42%
1J Leistung:
+39.57%
1-Tages-Spanne:
$47.54
$49.15
1-Wochen-Bereich:
$44.54
$49.15
52-Wochen-Spanne:
$28.72
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
48.89 | 3.61B | 900.66M | -453.20M | -274.19M | -5.94 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
State of Wyoming Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Two Sigma Investments LP Sells 143,945 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Woodline Partners LP Purchases Shares of 155,883 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Millennium Management LLC Has $13.97 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Bank of America Corp DE - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Holdings Lifted by ProShare Advisors LLC - MarketBeat
Wells Fargo & Company Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Cut by Two Sigma Advisers LP - MarketBeat
Voloridge Investment Management LLC Sells 92,168 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Price Target Raised by Wells Fargo | PTCT Stock News - GuruFocus
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
PTCT: Wells Fargo Increases Price Target for PTC Therapeutics | - GuruFocus
Toronto Dominion Bank Invests $148.36 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
9,656 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Quantinno Capital Management LP - MarketBeat
BNP Paribas Financial Markets Lowers Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Evolving Landscape of Mitochondrial Disease Market: Key Insights of Latest Published Report—Leigh Syndrome, Leber’s Hereditary Optic Neuropathy, MELAS Syndrome, and Thymidine Kinase 2 Deficiency | DelveInsight - GlobeNewswire Inc.
PTC Therapeutics’ SWOT analysis: biotech stock faces pivotal year amid pipeline progress By Investing.com - Investing.com South Africa
PTC Therapeutics’ SWOT analysis: biotech stock faces pivotal year amid pipeline progress - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - cnhinews.com
Nuveen Asset Management LLC Acquires 273,638 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Rafferty Asset Management LLC Reduces Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Lazard Asset Management LLC Has $2.06 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Muscular Dystrophy Treatment Market: Executive Briefing & - openPR.com
Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com
Those who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51% - Yahoo Finance
Deutsche Bank AG Has $4.26 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
StockNews.com Downgrades PTC Therapeutics (NASDAQ:PTCT) to Buy - MarketBeat
Point72 Asset Management L.P. Purchases 867,502 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Point72 Hong Kong Ltd Grows Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 02 - marketscreener.com
14,998 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Graham Capital Management L.P. - MarketBeat
Parkman Healthcare Partners LLC Decreases Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
2025-05-19 | PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:PTCT | Press Release - Stockhouse
MPM Bioimpact LLC Buys 345,052 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages PTC Therapeutics, Inc. (PTCT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results - Quantisnow
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down – Here’s What Happened - Defense World
Dimensional Fund Advisors LP Invests $4.74 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Holdings Raised by Northern Trust Corp - MarketBeat
Jacobs Levy Equity Management Inc. Sells 659,778 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Janus Henderson Group PLC Raises Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Buy at StockNews.com - Defense World
Friedreich Ataxia Marketed And Pipeline Drugs Analysis During - openPR.com
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):